Bacteroides thetaiotaomicron and Bacteroides ovatus for the treatment of MAFLD: A comparative study of individual and combined effects
- 12 April 2026
- journal article
- research article
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 157, 110377
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81402987)
- Key Research and Development Program of Sichuan Province (2022YFS0370)
This publication has 44 references indexed in Scilit:
- Bacteroides ovatus alleviates high-fat and high-cholesterol -induced nonalcoholic fatty liver disease via gut-liver axisBiomedicine & Pharmacotherapy, 2024
- Glucomannan promotes Bacteroides ovatus to improve intestinal barrier function and ameliorate insulin resistanceiMeta, 2024
- Noninvasive Assessment of Liver Fibrosis in NAFLDClinical Gastroenterology and Hepatology, 2023
- Gut-liver axis: Pathophysiological concepts and clinical implicationsCell Metabolism, 2022
- Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLDHepatology, 2022
- Bacteroides ovatus Promotes IL-22 Production and Reduces Trinitrobenzene Sulfonic Acid–Driven Colonic InflammationThe American Journal of Pathology, 2021
- Activation of a Specific Gut Bacteroides-Folate-Liver Axis Benefits for the Alleviation of Nonalcoholic Hepatic SteatosisCell Reports, 2020
- Novel strains of Bacteroides fragilis and Bacteroides ovatus alleviate the LPS-induced inflammation in miceApplied Microbiology and Biotechnology, 2019
- The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiotaHepatology, 2015
- Association of Obestatin, Ghrelin, and Inflammatory Cytokines in Obese Patients with Non-alcoholic Fatty Liver DiseaseObesity Surgery, 2011